SBIR/STTR Research Award
Clinical Evaluation of a Long Term Implanted Glucose Sensor
Award amount
$1,992,819Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GLYSENS, INC.
- Proposal award date
- 2014-09-19
- Contract end date
- 2016-09-18
- UEI
- Not reported
- Solicitation number
- PA13-088
- Topic code
- 200
Research abstract
DESCRIPTION provided by applicant Diabetes is a major healthcare problem that is reaching crisis proportions and new therapies are urgently needed We have developed a long term fully self contained glucose monitoring sensor with battery operated telemetry for implantation in subcutaneous tissues The sensor would have unique applications in type diabetes for hypoglycemia warning insulin dosing and control of the artificial pancreas The sensor may also have application for glucose monitoring in type diabetes caloric and activity management in obesity and prevention of type diabetes in susceptible individuals Development of this long term implantable glucose sensor has been underway for several years Following extensive preclinical validations in the first phase of this project including operation in animal implants of up to days in a second phase we demonstrated operation in a month FDA cleared first in human clinical trial In this clinical trial sensor telemetry unis implanted in humans for six months demonstrated calibration stability for periods of up to one month at a time the longest calibration interval examined The clinical trial also revealed a need for several simple but valuable sensor design revisions which have been completed and manifested in second generation devices now ready for human study In the proposed project we will verify acceptable performance of the second generation devices in a month human clinical feasibility trial which will include quantitative assessments of sensor accuracy and lag
The potential utility of the sensor for future application in closed loop systems will also be evaluated The long term implantable glucose sensor has an important role in the therapy for diabetes The sensor we are developing has undergone systematic engineering analysis extensive long term animal tests and initial long term human clinical study The proposed studies with the second generation sensor are designed to catalyze commercialization and accelerate delivery of the long term sensor into broad clinical practice PUBLIC HEALTH RELEVANCE Diabetes is a major healthcare problem that is reaching crisis proportions and new therapies are urgently needed In an initial six month human implant feasibility test we have demonstrated operation of a new long term fully implanted glucose sensor with unique applications in diabetes for hypoglycemia warning insulin dosing and control of the artificial pancreas In this proposed project we will verify acceptability and accuracy of a revised version of the sensor in a second human study
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment